Lilly, Isis form antisense alliance

LLY and ISIP formed an antisense therapeutic discovery collaboration, which includes LLY receiving exclusive worldwide rights to ISIP's ISIS 3521. The product, a selective inhibitor of PKC-alpha, is in Phase III testing for non-small cell lung cancer. In addition to the ISIS 3521 license, the companies signed a four-year collaboration to discover antisense compounds for metabolic and inflammatory diseases using ISIP's GeneTrove antisense technology. ...